Deutsche Märkte geschlossen

Becton, Dickinson and Company (BDX)

NYSE - NYSE Verzögerter Preis. Währung in USD
Zur Watchlist hinzufügen
234,12+0,97 (+0,42%)
Börsenschluss: 04:00PM EDT
234,12 0,00 (0,00%)
Nachbörse: 05:48PM EDT

Becton, Dickinson and Company

1 Becton Drive
Franklin Lakes, NJ 07417-1880
United States
201 847 6800
https://www.bd.com

Sektor(en)Healthcare
BrancheMedical Instruments & Supplies
Vollzeitmitarbeiter73.000

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Thomas E. Polen Jr.President, CEO & Chairman3,46MN/A1973
Mr. Christopher J. DelOreficeExecutive VP & CFO1,6MN/A1972
Ms. Shana Carol NealExecutive VP & Chief People Officer1,79MN/A1966
Mr. David B. HickeyExecutive VP & President of Life Sciences Segment1,11M562,03k1964
Mr. Michael GarrisonExecutive VP & President of Medical segment1,73MN/A1970
Mr. Thomas J. SpoerelSenior VP, Controller & Chief Accounting OfficerN/AN/A1979
Ms. Elizabeth McCombsExecutive VP & Chief Technology OfficerN/AN/A1976
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.Senior VP, Chief Scientific Officer & Co-Chair of Scientific Advisory BoardN/AN/AN/A
Ms. Denise Russell FlemingExecutive VP of Technology & Global Services and Chief Information OfficerN/AN/A1970
Mr. Greg RodetisHead of Investor RelationsN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Corporate Governance

Becton, Dickinson and Companys ISS Governance QualityScore, Stand 1. April 2024, lautet 10. Die grundlegenden Scores sind Audit: 10, Vorstand: 8, Shareholderrechte: 9, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.